Insights Series S3 E3: CEO Sten R. Sörensen on the exciting field of PAH

CEO Sten R. Sörensen highlights the remarkable early signs of efficacy in Cereno Scientific’s Phase II study with candidate drug CS1 in patients with PAH.

The Insights Series is conducted as a series of interviews and conversations with internationally renowned scientific experts, who share their knowledge and insights to provide a greater understanding of the company's intensified focus on further developing the product portfolio. Season 3 of the Video Series was recorded in conjunction with Cereno’s participation at the prestigious top global PVRI 2024 Annual Congress organized by the Pulmonary Vascular Research Institute. The PVRI 2024 Annual Congress is a top global pulmonary vascular congress, focusing on the future of care for patients with pulmonary hypertension and pulmonary vascular disease, gathering key opinion leaders from all over the world.